What is William Blair’s Estimate for ALNY FY2024 Earnings?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Research analysts at William Blair raised their FY2024 EPS estimates for shares of Alnylam Pharmaceuticals in a research report issued on Sunday, January 12th. William Blair analyst M. Minter now expects that the biopharmaceutical company will post earnings per share of ($2.01) for the year, up from their prior forecast of ($2.12). William Blair has a “Outperform” rating on the stock. The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($2.21) per share. William Blair also issued estimates for Alnylam Pharmaceuticals’ Q4 2024 earnings at ($0.48) EPS.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. The business’s quarterly revenue was down 33.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.15 EPS.

ALNY has been the subject of several other research reports. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $220.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, October 11th. Scotiabank boosted their target price on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the company a “sector outperform” rating in a research note on Friday, November 1st. HC Wainwright reissued a “buy” rating and issued a $400.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday. Sanford C. Bernstein cut their target price on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a research note on Tuesday, January 7th. Finally, Raymond James boosted their target price on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an “outperform” rating in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have assigned a buy rating to the stock. According to MarketBeat, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $298.61.

Alnylam Pharmaceuticals Trading Up 4.4 %

NASDAQ:ALNY opened at $251.01 on Wednesday. The company has a market capitalization of $32.38 billion, a PE ratio of -95.81 and a beta of 0.34. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. Alnylam Pharmaceuticals has a 52-week low of $141.98 and a 52-week high of $304.39. The stock has a fifty day simple moving average of $248.15 and a 200-day simple moving average of $259.81.

Insider Transactions at Alnylam Pharmaceuticals

In related news, EVP Tolga Tanguler sold 1,469 shares of the company’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $368,689.62. Following the sale, the executive vice president now owns 13,191 shares of the company’s stock, valued at $3,310,677.18. The trade was a 10.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CMO Pushkal Garg sold 1,682 shares of the business’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $422,148.36. Following the completion of the transaction, the chief marketing officer now owns 17,457 shares in the company, valued at approximately $4,381,357.86. This trade represents a 8.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 10,122 shares of company stock worth $2,540,455. 1.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Large investors have recently modified their holdings of the stock. Huntington National Bank lifted its position in shares of Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 45 shares in the last quarter. Hollencrest Capital Management bought a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth $29,000. Ashton Thomas Private Wealth LLC bought a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth $26,000. Washington Trust Advisors Inc. bought a new position in Alnylam Pharmaceuticals in the third quarter valued at $42,000. Finally, True Wealth Design LLC grew its position in Alnylam Pharmaceuticals by 15,300.0% in the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 153 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.